Intest Res.  2021 Jan;19(1):115-118. 10.5217/ir.2020.00030.

Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis

• Shimizu H
• Fujii T
• Hibiya S
• Motobayashi M
• Suzuki K
• Takenaka K
• Saito E
• Nagahori M
• Ohtsuka K
• Watanabe M

• KMID: 2512107
• DOI: http://doi.org/10.5217/ir.2020.00030

Figure

• 

  Fig. 1. Efficacy of tofacitinib. (A) Response and remission rates at 4 weeks were 40% and 20%, respectively, and both rates exceeded 40% from 8 to 52 weeks. (B) Responders at 4 weeks had significantly less discontinuation of tofacitinib until 52 weeks.

Reference

1. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012; 380:1606–1619.

2. Danese S, Grisham M, Hodge J, Telliez JB. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2016; 310:G155–G162.

3. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017; 376:1723–1736.

4. Sandborn WJ, Panés J, D’Haens GR, et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin Gastroenterol Hepatol. 2019; 17:1541–1550.

5. Suzuki Y, Watanabe M, Matsui T, et al. Tofacitinib as induction and maintenance therapy in Japanese patients with active ulcerative colitis. Inflamm Intest Dis. 2019; 4:131–143.

6. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353:2462–2476.

7. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med. 1987; 317:1625–1629.

8. D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007; 132:763–786.

9. Lair-Mehiri L, Stefanescu C, Vaysse T, et al. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Dig Liver Dis. 2020; 52:268–273.

10. Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019; 21:89.